Lower cost biosimilars can potentially enhance access/availability/usage of long-acting insulin analogues in suitable patients where there are concerns—especially given rising rates of diabetes across countries and issues of co-payments/affordability in a number of countries. The gene discussed is INS; the disease is diabetes mellitus.